4D Pharma PLC(LBPS)
1.65+0.000.00%
Market data delayed 15 minutes
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
Company Profile
Company Name4D Pharma PLCMarketNASDAQEstablishment Date- -Employees- -Office Location- -WebsiteZip Code- -Phone- -Fax- -Introduction4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.- 2022-07-1925-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesDelisting25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
- 2022-04-26CORRESP [Cover] - CorrespondenceCorrespondenceCORRESP [Cover] - Correspondence
- 2022-04-01S-8 - Securities to be offered to employees in employee benefit plansEmployee Stock OwnershipS-8 - Securities to be offered to employees in employee benefit plans
- 2022-03-3120-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]Annual Report20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2022-03-28CORRESP [Cover] - CorrespondenceCorrespondenceCORRESP [Cover] - Correspondence
- 2022-03-02SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeSC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
- 2022-02-28SC 13G - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeSC 13G - Statement of acquisition of beneficial ownership by individuals
- 2022-02-25SC 13G - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeSC 13G - Statement of acquisition of beneficial ownership by individuals
- 2022-02-03SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeSC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
- 2022-02-02SC 13G - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeSC 13G - Statement of acquisition of beneficial ownership by individuals
- 2021-10-12CORRESP [Cover] - CorrespondenceCorrespondenceCORRESP [Cover] - Correspondence
- 2021-10-07F-1/A [Amend] - Registration statement for certain foreign private issuers[Amend]Public ProspectusF-1/A [Amend] - Registration statement for certain foreign private issuers
- 2021-09-14F-1 - Registration statement for certain foreign private issuersPublic ProspectusF-1 - Registration statement for certain foreign private issuers
- 2021-05-21CORRESP [Cover] - CorrespondenceCorrespondenceCORRESP [Cover] - Correspondence
- 2021-05-21CORRESP [Cover] - CorrespondenceCorrespondenceCORRESP [Cover] - Correspondence
- 1D
- 5D
- Day
- Week
- Month
Loading ...
High
1.65
Open
1.65
Volume%
0.09
Low
1.65
Close
1.65
T/O Rate
0.00%